107 related articles for article (PubMed ID: 28646023)
61. Interaction of S100A6 with Target Proteins In Vitro and in Living Cells.
Sakane K; Yamaguchi F; Tsuchiya M; Kondo R; Kanayama N; Magari M; Hatano N; Kobayashi R; Tokumitsu H
Methods Mol Biol; 2019; 1929():367-377. PubMed ID: 30710285
[TBL] [Abstract][Full Text] [Related]
62. Kiss of death between CAR-T cells and KMT2a::AFF1 B lymphoblasts in the central nervous system.
Fenneteau O; Lainey E
Am J Hematol; 2023 Nov; 98(11):1816-1817. PubMed ID: 37340822
[No Abstract] [Full Text] [Related]
63. Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease.
Dosanjh A; Won CY
Yale J Biol Med; 2020 Dec; 93(5):759-763. PubMed ID: 33380937
[TBL] [Abstract][Full Text] [Related]
64. [Expression Level of S100A6 mRNA in MM and Its Clinical Significance].
Bao HY; Wang JN; Meng QQ; Song M; Fu XC; Hou YQ; Zhang LB; Jiang SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1466-1469. PubMed ID: 27784376
[TBL] [Abstract][Full Text] [Related]
65. Systematic
Karsa M; Ronca E; Bongers A; Mariana A; Moles E; Failes TW; Arndt GM; Cheung LC; Kotecha RS; Kavallaris M; Haber M; Norris MD; Henderson MJ; Xiao L; Somers K
Front Oncol; 2021; 11():779859. PubMed ID: 35127484
[TBL] [Abstract][Full Text] [Related]
66. Synthesis of deuterium-labelled amlexanox and its metabolic stability against mouse, rat, and human microsomes.
Gan X; Wilson MW; Beyett TS; Wen B; Sun D; Larsen SD; Tesmer JJG; Saltiel AR; Showalter HD
J Labelled Comp Radiopharm; 2019 May; 62(5):202-208. PubMed ID: 30828860
[TBL] [Abstract][Full Text] [Related]
67. XRCC4 rs28360071 intronic variant is associated with increased risk for infant acute lymphoblastic leukemia with KMT2A rearrangements.
Louzada-Neto O; Lopes BA; Brisson GD; Andrade FG; Cezar IS; Santos-Rebouças CB; Albano RM; Pombo-de-Oliveira MS; Rossini A
Genet Mol Biol; 2020; 43(4):e20200160. PubMed ID: 33270074
[TBL] [Abstract][Full Text] [Related]
68. The Partial Duplication of the 5' Segment of
Fukushima H; Nanmoku T; Hosaka S; Yamaki Y; Kiyokawa N; Fukushima T; Sumazaki R
Case Rep Pediatr; 2017; 2017():6257494. PubMed ID: 29445560
[TBL] [Abstract][Full Text] [Related]
69. Dysregulated transcriptional networks in
Kang H; Sharma ND; Nickl CK; Devidas M; Loh ML; Hunger SP; Dunsmore KP; Winter SS; Matlawska-Wasowska K
Biomark Res; 2018; 6():27. PubMed ID: 30159143
[TBL] [Abstract][Full Text] [Related]
70. DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity.
Anchang B; Davis KL; Fienberg HG; Williamson BD; Bendall SC; Karacosta LG; Tibshirani R; Nolan GP; Plevritis SK
Proc Natl Acad Sci U S A; 2018 May; 115(18):E4294-E4303. PubMed ID: 29654148
[TBL] [Abstract][Full Text] [Related]
71. Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
Leukemia; 2021 May; 35(5):1527. PubMed ID: 33846544
[No Abstract] [Full Text] [Related]
72. Lineage switch from B lymphoblastic leukemia with
Marco-Ayala J; Vicente AI; Such E; Luna I; Andreu R; Sempere A; Romero S; Peris MLS
Blood Res; 2020 Jun; 55(2):75. PubMed ID: 32375465
[No Abstract] [Full Text] [Related]
73. Author Correction: Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
Nat Commun; 2023 Mar; 14(1):1297. PubMed ID: 36894563
[No Abstract] [Full Text] [Related]
74. Correction to: Dysplastic features seen in a patient with acute myeloid leukemia harboring the KMT2A-TET1 fusion gene.
Kawai H; Matsushita H; Aoyama Y; Matsui K; Onizuka M; Ando K
Int J Hematol; 2018 Aug; 108(2):232. PubMed ID: 29948955
[TBL] [Abstract][Full Text] [Related]
75. Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15 years.
Aubrey C; Mal H; Köbel M; Lee CH; Turashvili G; Yip S; Lum A; Nelson G
Gynecol Oncol Rep; 2021 Nov; 38():100890. PubMed ID: 34926770
[TBL] [Abstract][Full Text] [Related]
76. Palbociclib in Acute Leukemias With
Gaidzik VI; Paschka P; Schlenk RF; Weber D; Fröhling S; Krämer A; Wäsch R; Westermann J; Mayer K; de Wit M; Fiedler W; Benner A; Heuser M; Thol F; Döhner K; Ganser A; Döhner H
Hemasphere; 2023 May; 7(5):e877. PubMed ID: 37101762
[No Abstract] [Full Text] [Related]
77. Obesity: Teaching an old drug new tricks--amlexanox targets inflammation to improve metabolic dysfunction.
Koch L
Nat Rev Endocrinol; 2013 Apr; 9(4):185. PubMed ID: 23438840
[No Abstract] [Full Text] [Related]
78. Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines.
Liu Y; Lu J; Zhang Z; Zhu L; Dong S; Guo G; Li R; Nan Y; Yu K; Zhong Y; Huang Q
Cell Death Dis; 2017 Aug; 8(8):e3022. PubMed ID: 29048430
[TBL] [Abstract][Full Text] [Related]
79. The role of TBK1 in cancer pathogenesis and anticancer immunity.
Runde AP; Mack R; S J PB; Zhang J
J Exp Clin Cancer Res; 2022 Apr; 41(1):135. PubMed ID: 35395857
[TBL] [Abstract][Full Text] [Related]
80. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.
Zhu L; Li Y; Xie X; Zhou X; Gu M; Jie Z; Ko CJ; Gao T; Hernandez BE; Cheng X; Sun SC
Nat Cell Biol; 2019 Dec; 21(12):1604-1614. PubMed ID: 31792381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
